首页 工具
登录
购物车
Paquinimod

Paquinimod

产品编号 T7310   CAS 248282-01-1
别名: 帕奎莫德, ABR 25757

Paquinimod (ABR 25757) 是一种特异性的 S100A8/S100A9 抑制剂,能够减少 SARS-CoV-2 感染小鼠的病毒载量,可用于研究肺炎。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
Paquinimod Chemical Structure
Paquinimod, CAS 248282-01-1
规格 价格/CNY 货期 数量
1 mg ¥ 286 现货
5 mg ¥ 673 现货
10 mg ¥ 987 现货
25 mg ¥ 1,980 现货
50 mg ¥ 3,630 现货
100 mg ¥ 4,680 现货
1 mL * 10 mM (in DMSO) ¥ 792 现货
千万补贴 助力科研
BCA蛋白浓度测定试剂盒限时半价
重组蛋白限时优惠
Doxorubicin hydrochloride限时半价
产品目录号及名称: Paquinimod (T7310)
点击图片重新获取验证码
选择批次  
纯度: 99.79%
纯度: 99.61%
纯度: 98.04%
纯度: 97.62%
TargetMol batch loading
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 Paquinimod (ABR 25757) is a S100A9 inhibitor preventing S100A9 binding to TLR-4.
体内活性 Prophylactic treatment of paquinimod reduces synovial activation, osteophyte formation and cartilage damage in experimental OA with high synovial activation (CIOA) and ameliorates pathological effects of S100A9 in OA synovium ex vivo[1].Treatment with paquinimod reduces skin fibrosis measured as reduction of skin thickness and decreased number of myofibroblasts and total hydroxyproline content. The effect on fibrosis was associated with a polarization of macrophages in the skin from a pro-fibrotic M2 to a M1 phenotype. Paquinimod treatment also resulted in a reduced TGFβ-response in the skin and an abrogation of the increased auto-antibody production in this SSc model[1].
动物实验 Two OA mouse models differing in level of synovial activation were treated prophylactic with paquinimod. Synovial thickening, osteophyte size and cartilage damage were measured histologically, using an arbitrary score, adapted Pritzker OARSI score or imaging software, respectively. Human OA synovia were stimulated with S100A9, with or without paquinimod[1].Seven weeks old female B6.Cg-Fbn1(Tsk)/J (Tsk-1) mice were treated with vehicle or paquinimod at the dose of 5 or 25mg/kg/day in the drinking water for 8 weeks. The effect of paquinimod on the level of skin fibrosis and on different subpopulations within the myeloid cell compartment in skin biopsies were evaluated by using histology, immunohistochemisty, a hydroxyproline assay and real-time PCR. Furthermore, the level of IgG in serum from treated animals was also analysed. The statistical analyses were performed using Mann-Whitney nonparametric two tailed rank test[1].
别名 帕奎莫德, ABR 25757
分子量 350.41
分子式 C21H22N2O3
CAS No. 248282-01-1

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

DMSO: 125 mg/mL (356.72 mM)

溶液配制表

可选溶剂 浓度 体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.8538 mL 14.269 mL 28.538 mL 71.345 mL
5 mM 0.5708 mL 2.8538 mL 5.7076 mL 14.269 mL
10 mM 0.2854 mL 1.4269 mL 2.8538 mL 7.1345 mL
20 mM 0.1427 mL 0.7134 mL 1.4269 mL 3.5672 mL
50 mM 0.0571 mL 0.2854 mL 0.5708 mL 1.4269 mL
100 mM 0.0285 mL 0.1427 mL 0.2854 mL 0.7134 mL

TargetMol Calculator计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

TargetMol Library Books参考文献

1. Schelbergen R F , Geven E J , Van d B M H J , et al. Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis[J]. Annals of the Rheumatic Diseases, 2015:annrheumdis-2014-206517. 2. StenstrM M , Nyhlén, Helén Carlsson, T?Rngren M , et al. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis[J]. Journal of Dermatological Science, 2016:S0923181116300615. 3. Guo Q, Zhao Y, Li J, et al. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19[J]. Cell Host & Microbe . 2020

TargetMol Library Books文献引用

1. Guo Q, Zhao Y, Li J, et al. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19. Cell Host & Microbe. 2020 2. Jiang H, Zhao Y, Su M, et al.A proteome-wide screen identifies the calcium binding proteins, S100A8/S100A9, as clinically relevant therapeutic targets in aortic dissection.Pharmacological Research.2023: 107029.

相关化合物库

该产品包含在如下化合物库中:
抑制剂库 药物功能重定位化合物库 已知活性化合物库 抗病毒库 经典已知活性库 ReFRAME 相关化合物库 临床期小分子药物库 NO PAINS 化合物库 人代谢物化合物库

TargetMol Calculator剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

TargetMol Calculator 体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

Paquinimod 248282-01-1 Others Inhibitor inhibit 帕奎莫德 ABR25757 ABR-25757 ABR 25757 inhibitor

 

TargetMol Loading
陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼